Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia?

Medical Hypotheses

Volumn 76, Issue 5, 2011, Pages 618-621

  Feng, Sara ^a   Huang, Yihong ^b   Chen, Zixing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; CYTOPLASM PROTEIN; MEMBRANE PROTEIN; OCCLUDIN; PROTEIN ZO1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD VESSEL; CANCER INFILTRATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM LEUKEMIA; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MORBIDITY; MORTALITY; NONHUMAN; PHENOTYPE; PROTEIN SECRETION; TIGHT JUNCTION; TUMOR GROWTH;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBROVASCULAR CIRCULATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEOPLASM METASTASIS; PERMEABILITY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 79954415296     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.12.001     Document Type: Article

References (34)

1. Kaspers G., Gibson B., Grimwade D., Pession A., Smith O., Testi A.M. Central nervous system involvement in relapsed acute promyelocytic leukemia. Pediatr Blood Cancer 2009, 53(2):235-236. PMID: 19353622.
2. Laningham F.H., Kun L.E., Reddick W.E., et al. Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 2007, 49(11):873-878. PMID: 17924103.
3. Pui C.H., Howard S.C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008, 9(3):257-268. PMID: 18308251.
4. Johnston D.L., Alonzo T.A., Gerbing R.B., Lange B.J., Woods W.G. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 2005, 23(36):9172-9178. PMID: 16361619.
5. Sancho J.M., Ribera J.M., Oriol A., et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer 2006, 106(12):2540-2546. PMID: 16700036.
6. Tsurusawa M., Yumura-Yagi K., Ohara A., et al. Survival outcome after the first central nervous system relapse in children with acute lymphoblastic leukemia: a retrospective analysis of 79 patients in a joint program involving the experience of three Japanese study groups. Int J Hematol 2007, 85(1):36-40. PMID: 17261500.
7. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57(2):178-201. PMID: 18215617.
8. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027. PMID: 15585754.
9. Chi O.Z., Hunter C., Liu X., Weiss H.R. Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia. Exp Neurol 2007, 204(1):283-287. PMID: 18708733.
10. Argaw A.T., Gurfein B.T., Zhang Y., Zameer A., John G.R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 2009, 106(6):1977-1982. PMID: 19174516.
11. Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96(6):2240-2245. PMID: 10979972.
12. Wegiel B., Ekberg J., Talasila K.M., Jalili S., Persson J.L. The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. Leukemia 2009, 23(2):251-261. PMID: 18987662.
13. Poyer F., Coquerel B., Pegahi R., et al. Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk Res 2009, 33(3):407-417. PMID: 18829111.
14. Zhu Z., Hattori K., Zhang H., et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003, 17(3):604-611. PMID: 12646950.
15. Thomas X., Le Q.H. Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology 2008, 13(5):293-302. PMID: 18854093.
16. Laningham F.H., Kun L.E., Reddick W.E., Ogg R.J., Morris E.B., Pui C.H. Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 2007, 49(11):873-888. PMID: 17924103.
17. Montesinos P., Díaz-Mediavilla J., Debén G., et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 2009, 94(9):1242-1249. PMID: 19608685.
18. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354(2):166-178. PMID: 16407512.
19. Sancho J.M., Deben G., Parker A., et al. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis. Int J Hematol 2007, 86(1):33-36. PMID: 17675264.
20. Pardridge W.M. Blood-brain barrier delivery. Drug Discov Today 2007, 12(1-2):54-61. PMID: 17198973.
21. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57(2):173-185. PMID: 15914466.
22. Saunders N.R., Ek C.J., Habgood M.D., Dziegielewska K.M. Barriers in the brain: a renaissance?. Trends Neurosci 2008, 31(6):279-286. PMID: 18471905.
23. Martin T.A., Mansel R.E., Jiang W.G. Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells. J Cell Physiol 2002, 192(3):268-275. PMID: 12124772.
24. Ueda J., Semba S., Chiba H., Sawada N., Seo Y., Kasuga M., et al. Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 2007, 74(1):32-41. PMID: 17496431.
25. Osanai M., Murata M., Nishikiori N., Chiba H., Kojima T., Sawada N. Occludin-mediated premature senescence is a fail-safe mechanism against tumorigenesis in breast carcinoma cells. Cancer Sci 2007, 98(7):1027-1034. PMID: 17459053.
26. Morgan L., Shah B., Rivers L.E., Barden L., Groom A.J., et al. Chung R Inflammation and dephosphorylation of the tight junction protein occludin in an experimental model of multiple sclerosis. Neuroscience 2007, 147(3):664-673. PMID: 17560040.
27. Tsukita S., Furuse M. Claudin-based barrier in simple and stratified cellular sheets. Ts Curr Opin Cell Biol 2002, 14(5):531-536. PMID: 12231346.
28. Morita K., Sasaki H., Furuse M., Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 1999, 147(1):185-194. PMID: 10508865.
29. Furuse M., Hirase T., Itoh M., Nagafuchi A., Yonemura S., Tsukita S., et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993, 123(6 Pt. 2):1777-1788. PMID: 8276896.
30. Hawkins B.T., Lundeen T.F., Norwood K.M., Brooks H.L., Egleton R.D. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007, 50(1):202-211. PMID: 17143608.
31. Pedram A., Razandi M., Levin E.R. Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. Diabetologia 2007, 50(1):202-211. PMID: 12213803.
32. Jubb A.M., Oates A.J., Holden S., Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006, 6(8):626-635. PMID: 16837971.
33. Kessler T., Fehrmann F., Bieker R., Berdel W.E., Mesters R.M. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets 2007, 8(2):257-268. PMID: 17305503.
34. Li W.W., Hutnik M., Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol 2008, 143(5):622-631. PMID: 19036013.